Theravance Biopharma and Mylan announced that the U.S. Food and Drug Administration (FDA) approved their New Drug Application (NDA) for revefenacin (TD-4208) as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The therapy will be marketed as an inhalation solution with the brand name Yupelri. The…
The COPD Foundation has launched an app called the COPD Pocket Consultant Guide (PCG), designed to help healthcare providers in the treatment and management of patients with chronic obstructive pulmonary disease (COPD). Links to download the app, either for Android or iOS, can be found here. The main features…
Treatment administration has started in the second part of a Phase 2 trial evaluating the safety and efficacy of Synairgen‘s inhaled therapeutic candidate SNG001 in patients with chronic obstructive pulmonary disease (COPD) with a confirmed flu or cold virus. SNG001 is an inhaled interferon-beta (IFN-beta) therapy developed to help…
Long-term oxygen therapy may not benefit patients with mild to moderate chronic obstructive pulmonary disease (COPD) with low levels of oxygen in the blood (hypoxemia), a meta-analysis has shown. This type of therapy did not prolong life expectancy or decrease the risk of hospitalization in these patients, and did not…
Patients with chronic obstructive pulmonary disease (COPD) on long-term treatment with benzodiazepines are at a higher risk for suicide, a study suggests. The study, “Risks of Benzodiazepines in Chronic Obstructive Pulmonary Disease with Comorbid Posttraumatic Stress Disorder,” was published in the journal Annals of the American Thoracic Society.
The U.S. Food and Drug Administration (FDA) approved a new label for Stiolto Respimat (a combination therapy of tiotropium bromide and olodaterol) based on data from clinical trials showing a significant reduction in the frequency of chronic obstructive pulmonary disease (COPD) exacerbations driven by tiotropium, the active ingredient of …
A fully functional 3D-printed artificial lung may someday help people with serious pulmonary illnesses, such as chronic obstructive pulmonary disease (COPD). A Department of Veterans Affairs (VA) research team, in collaboration with Old World Labs — a company in Hampton, Virginia, specializing in high-resolution 3D printing — is working to…
The triple therapy inhaler Trelegy Ellipta (fluticasone furoate, umeclidinium, vilanterol) has received a positive recommendation from the European Medicines Agency (EMA)‘s Committee for Medicinal Products for Human Use (CHMP) to expand its use to a broader population of chronic obstructive pulmonary disease (COPD) patients.
The benefits of Daliresp (roflumilast), an approved chronic obstructive pulmonary disease therapy, may include an anti-inflammatory effect, with the treatment seen in a Phase 3 clinical trial to lower the number of eosinophils — a type of immune cell linked to inflammation — in the lungs of patients with moderate to severe…
AstraZeneca’s triple combination therapy PT010 (budesonide/glycopyrrolate/formoterol fumarate) improved lung function and reduced the rate of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in a Phase 3 trial, compared with dual combination therapies. Results of the trial were published in the study, “Triple…
Get regular updates to your inbox.